Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 7/20 | 0.58 |
| ▸ | DYRK2 | Q92630 | 3/20 | 0.58 |
| ▸ | RAF1 | P04049 | 2/20 | 0.58 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | AKT1 | P31749 | 2/20 | 0.58 |
| ▸ | AKT2 | P31751 | 2/20 | 0.58 |
| ▸ | KDR | P35968 | 2/20 | 0.58 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.58 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.58 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.58 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.58 |
| ▸ | NEK1 | Q96PY6 | 2/20 | 0.58 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.58 |
| ▸ | TNF | P01375 | 3/20 | 0.54 |
| ▸ | IL6 | P05231 | 3/20 | 0.54 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.48 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.41 |
| ▸ | MYC | P01106 | 1/20 | 0.39 |
| ▸ | MAX | P61244 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13036876 | 1.00 | IKBKB (0.58) | IKBKBDYRK2RAF1RPS6KB1MAPK1 | |
| SCHEMBL8122478 | 0.86 | TNF (0.71) | IKBKBDYRK2RAF1RPS6KB1MAPK1 | |
| SCHEMBL27967110 | 0.86 | TNF (0.71) | IKBKBDYRK2RAF1RPS6KB1MAPK1 | |
| Hydrochloric Acid SCHEMBL27967262 | 0.84 | TNF (0.69) | IKBKBDYRK2RAF1RPS6KB1MAPK1 | |
| SCHEMBL21232738 | 0.84 | DYRK2 (0.56) | IKBKBDYRK2RAF1RPS6KB1MAPK1 | |
| SCHEMBL8116186 | 0.80 | IKBKB (0.39) | IKBKBDYRK2RAF1RPS6KB1MAPK1 | |
| SCHEMBL13074082 | 0.76 | TNF (0.58) | IKBKBDYRK2RAF1RPS6KB1MAPK1 | |
| SCHEMBL30593591 | 0.74 | IKBKB (1.00) | IKBKBDYRK2RAF1RPS6KB1MAPK1 | |
| SCHEMBL1325644 | 0.74 | IKBKB (1.00) | IKBKBDYRK2RAF1RPS6KB1MAPK1 | |
| SCHEMBL29363457 | 0.74 | IKBKB (1.00) | IKBKBDYRK2RAF1RPS6KB1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842705-B2 | Curcumin analogs with anti-tumor and anti-angiogenic properties | EMORY UNIVERSITY (US) | 2010-11-30 | — | — | US | disclosed |
| US-20080234320-A1 | CURCUMIN ANALOGS WITH ANTI-TUMOR AND ANTI-ANGIOGENIC PROPERTIES | EMORY UNIVERSITY | 2008-09-25 | — | — | US | disclosed |
| US-7371766-B2 | Curcumin analogs with anti-tumor and anti-angiogenic properties | EMORY UNIVERSITY (US) | 2008-05-13 | — | — | US | disclosed |
| US-20040176384-A1 | Curcumin analogs with anti-tumor and anti-angiogenic properties | EMORY UNIVERSITY | 2004-09-09 | — | — | US | disclosed |
| US-6664272-B2 | Such as 1,5-Bis-(2, 4-difluorophenyl)penta-1,4-diene-3 -one; administering to inhibit tissue factor and vascular endothelial growth factor (VEGF) production in cancerous tissue | EMORY UNIVERSITY | 2003-12-16 | — | — | US | disclosed |
| EP-1242379-A1 | CURCUMIN ANALOGUES FOR TREATING CANCER | Emory University (US) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001040188-A9 | CURCUMIN ANALOGUES FOR TREATING CANCER | UNIV EMORY (US) | 2002-07-25 | — | — | WO | disclosed |
| US-20020019382-A1 | Curcumin analogs with anti-tumor and anti-angiogenic properties | EMORY UNIVERSITY | 2002-02-14 | — | — | US | disclosed |
| WO-2001040188-A1 | CURCUMIN ANALOGUES FOR TREATING CANCER | EMORY UNIVERSITY (US) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176384-A1 | Curcumin analogs with anti-tumor and anti-angiogenic properties | PGF, VEGFA, VHL | IKBKB 178/4885DYRK2 4753/4885RAF1 4090/4885 |
| US-20080234320-A1 | CURCUMIN ANALOGS WITH ANTI-TUMOR AND ANTI-ANGIOGENIC PROPERTIES | PGF, VEGFA, VHL | IKBKB 178/4885DYRK2 4753/4885RAF1 4090/4885 |
| US-20020019382-A1 | Curcumin analogs with anti-tumor and anti-angiogenic properties | PGF, VEGFA, VHL | IKBKB 178/4885DYRK2 4753/4885RAF1 4090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.